Popular on TelAve
- EclecticIQ launches version 3.0 of its flagship threat intelligence platform, Intelligence Center
- Job Search Trends Highlight Shift Toward Sustainability and Automation in Engineering and Manufacturing Sectors
- Industrial and systems engineers head to New Orleans for major international conference
- TenCate Advanced Armour Begins Manufacturing Armour for Spain's Dragon VCR Vehicle
- What Donald Trump Doesn't Seem To Know About Women
- AMBER Lucid ONE, first choice for bioinspired Robot's arm, launches on Kickstarter
- Ten-8 Fire & Safety Joins the BME Fire Trucks Dealer Network
- Expereo unveils refreshed brand reflecting company's focus on the global future of connectivity
- Quad City Real Estate Agent Drastically Increases Interest in Homes
- Actionstep Academy Provides Added Training Value to Platform Customers
Similar on TelAve
- Financial IT Launches Fintech Pathfinder: Showcasing the Most Promising Fintech Startups
- KYC2020 Offers Free Sanctions Screening for Non-Commercial Use
- Bent Danholm of MAXIM Realty Orlando Joins Forces With Tech Company to Improve Target Marketing of Homes in Central Florida
- Stapleton Group and Sorokin & Associates Announce Strategic Partnership
- Jill Zarin, Star of The Real Housewives of NY, Launches Jill Zarin Beauty – A Luxurious Skincare Line Featuring Essential Products for Radiant Skin
- Angie Wong former Legacy PAC president steps down from L-Strategies consulting firm
- Billboard, Music Week, and DJ Times Charting Recording Artist, NOAH, Releases Groundbreaking Single "BABYMAKER"
- Calvetta Phair, CEO of America's Workforce Solution, LLC, accepted into the Nasdaq Entrepreneurial Center, 'Milestone Circles' Program
- Trump Bus Tour sponsored by Legacy PAC will roll into the Georgia GOP State convention June 9th and 10th Columbus Georgia
- Orbex Launches New ZERO Spread Trading Account with $1 Commission per Side
OrPro Therapeutics Receives $2.147M Therapeutic Development Funding from US Department of Defense for COVID-19 and Influenza
TelAve News/10750491
Prestigious CDMRP award will advance development of ORP100S as an inhaled treatment for acute and chronic respiratory diseases
SAN DIEGO - TelAve -- OrPro Therapeutics, Inc., a San Diego Johnson & Johnson JLABS alumni and 2022 SD CONNECT Cool Company, is pleased to announce that it has been awarded a Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development grant under the Congressionally Directed Medical Research Program (CDMRP) of the US Department of Defense. This $2.147M award entitled "Development of Monothiol Human Thioredoxin-1 (ORP100S) as an Inhaled Treatment for Acute Viral Lung Injury" involves OrPro researchers and collaborators at the Institute for Airway Sciences in the Icahn School of Medicine at Mount Sinai (New York, NY), Lovelace Biomedical (Albuquerque, NM), and KCAS Bioanalytical Services (Olathe, KS). Project advisors include innate immunity opinion leader Dr. Richard Ulevitch, Professor and former Chair of the Department of Immunology at Scripps Research; 3-D stem cell derived human lung organoid pioneer Dr. Ya-Wen Chen at Mount Sinai; and internationally recognized inhalation toxicology expert Dr. Jeffrey Tepper.
The objective of the grant-funded research is to understand the pharmacodynamic effect of ORP100S in vitro and in vivo for treatment of relevant viral diseases (COVID-19 and influenza), as well as to establish a validated bioanalytical method for the detection and quantification of ORP100S in plasma/serum and lung matrices from humans and non-clinical toxicology species. These objectives represent key ORP100S development milestones toward a US FDA Investigational New Drug (IND) filing and human clinical trials.
More on TelAve News
"CDMRP funding is highly competitive. Our team is tremendously excited to be recognized by the Department of Defense for the potential of our drug platform to impact respiratory health by filling a critical gap in the prevention of lung injury associated with viral infection and inflammation," said Dr. Peter Heifetz, Founder, President and CEO of OrPro Therapeutics. "This award will enable us to rapidly advance ORP100S for multiple indications with high unmet medical need."
"Our 3-D human lung organoid system has been proven to accurately recapitulate respiratory viral infection and host responses, making it ideal for evaluation of the efficacy and mechanism of novel therapeutics. I am looking forward to working with Principal Investigator Dr. Heifetz and the project team to combine our in vitro human system with parallel in vivo studies in relevant animal infection models, said Dr. Ya-Wen Chen, Assistant Professor, Icahn School of Medicine at Mount Sinai. "This dual approach has great promise for enabling successful translation to clinical studies."
Thioredoxin
Secreted human thioredoxin (TRX) is a target-selective thiol-disulfide exchange enzyme that acts homeostatically to modulate inflammatory cytokine release, oxidative stress, and abnormal airway mucus viscoelasticity via regulatory interaction with extracellular cell-surface protein disulfides. TRX lowers inflammation in acute lung injury, and published studies show it can prevent viral pneumonia and increase survival in influenza-infected animal models. OrPro has developed the proprietary Theradux® platform of TRX derivatives optimized for extracellular delivery and function with increased half-life and decreased potential for intracellular uptake and off-target activity. Lead development candidate ORP100S is highly active extracellularly as a cell protectant without promoting cellular proliferation and is being advanced as an inhaled nebulized solution for treatment of acute and chronic obstructive/inflammatory airway diseases.
More on TelAve News
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel biologic drug platform for treating severe respiratory, ophthalmic, and mucosal diseases. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the leading US respiratory research center, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $7M raised to date. For more information visit www.orprotherapeutics.com.
Contact
Peter Heifetz, Ph.D. OrPro Therapeutics, Inc. pheifetz@orprotherapeutics.com;
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
The objective of the grant-funded research is to understand the pharmacodynamic effect of ORP100S in vitro and in vivo for treatment of relevant viral diseases (COVID-19 and influenza), as well as to establish a validated bioanalytical method for the detection and quantification of ORP100S in plasma/serum and lung matrices from humans and non-clinical toxicology species. These objectives represent key ORP100S development milestones toward a US FDA Investigational New Drug (IND) filing and human clinical trials.
More on TelAve News
- IPD Announces Relocation of Headquarters to Carson, CA, Marking a Historic Milestone
- netElastic Achieves 1 Terabit Throughput on its Leading-Edge vBNG
- AIntelligent Studios Agency Launches to Disrupt Marketing
- Dog Door in Screen Door solution for pet owners
- KYC2020 Offers Free Sanctions Screening for Non-Commercial Use
"CDMRP funding is highly competitive. Our team is tremendously excited to be recognized by the Department of Defense for the potential of our drug platform to impact respiratory health by filling a critical gap in the prevention of lung injury associated with viral infection and inflammation," said Dr. Peter Heifetz, Founder, President and CEO of OrPro Therapeutics. "This award will enable us to rapidly advance ORP100S for multiple indications with high unmet medical need."
"Our 3-D human lung organoid system has been proven to accurately recapitulate respiratory viral infection and host responses, making it ideal for evaluation of the efficacy and mechanism of novel therapeutics. I am looking forward to working with Principal Investigator Dr. Heifetz and the project team to combine our in vitro human system with parallel in vivo studies in relevant animal infection models, said Dr. Ya-Wen Chen, Assistant Professor, Icahn School of Medicine at Mount Sinai. "This dual approach has great promise for enabling successful translation to clinical studies."
Thioredoxin
Secreted human thioredoxin (TRX) is a target-selective thiol-disulfide exchange enzyme that acts homeostatically to modulate inflammatory cytokine release, oxidative stress, and abnormal airway mucus viscoelasticity via regulatory interaction with extracellular cell-surface protein disulfides. TRX lowers inflammation in acute lung injury, and published studies show it can prevent viral pneumonia and increase survival in influenza-infected animal models. OrPro has developed the proprietary Theradux® platform of TRX derivatives optimized for extracellular delivery and function with increased half-life and decreased potential for intracellular uptake and off-target activity. Lead development candidate ORP100S is highly active extracellularly as a cell protectant without promoting cellular proliferation and is being advanced as an inhaled nebulized solution for treatment of acute and chronic obstructive/inflammatory airway diseases.
More on TelAve News
- Introducing RecipeNFT: The Revolutionary Platform for Preserving Family Recipes on the Avalanche Blockchain
- Introducing Obitz.io: Revolutionizing Obituaries with Blockchain Technology
- Bent Danholm of MAXIM Realty Orlando Joins Forces With Tech Company to Improve Target Marketing of Homes in Central Florida
- Stapleton Group and Sorokin & Associates Announce Strategic Partnership
- Jill Zarin, Star of The Real Housewives of NY, Launches Jill Zarin Beauty – A Luxurious Skincare Line Featuring Essential Products for Radiant Skin
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel biologic drug platform for treating severe respiratory, ophthalmic, and mucosal diseases. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the leading US respiratory research center, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $7M raised to date. For more information visit www.orprotherapeutics.com.
Contact
Peter Heifetz, Ph.D. OrPro Therapeutics, Inc. pheifetz@orprotherapeutics.com;
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
Source: OrPro Therapeutics
0 Comments
Latest on TelAve News
- Perfect Ffit: the new mobile game that puts your timing and strategy skills to the test. Can you get a Perfect Fit?
- Aquia Launches Amazon Web Services (AWS) Cloud Security Assessment Offering, Pairing Automation With Deep Cloud Security Expertise
- Orbex Launches New ZERO Spread Trading Account with $1 Commission per Side
- Alpha Gold Fund Receives Recognition Of Excellence Awards
- Ohio County Commission President & Founder of the Cincinnati Black Music Walk of Fame, Alicia Reece, Announces Grand Opening of New Tourism Attraction
- New York Komedians Presents an Evening of Laughs at Broadway
- Redefining Professional Spaces: The Rise of Dual-Purpose Backyard Office Sheds in America
- Registration is Now Open for the 2023 CGI Integrated Care Conference
- Studeo dévoile StudAI : l'Intelligence Artificielle au service de l'éducation
- EMH Productions Announce 'Live for Liberty' Charity Concert in Los Angeles Supporting "Woman, Life, Freedom" Movement in Iran
- NEMTAC® Brings Innovation to Accreditation Industry with the Launch of Collaborative Network Built on Distributed Ledger Technology
- Latino Leaders Network to Honor Mayor Kate Gallego of Phoenix with the Antonio Villaraigosa Leadership Award at the 38th Tribute to Mayors
- Century Fasteners Corp. – Robert D. Botticelli, Hired
- Levinger-Regens Analytics Reveals New Energy Outlook
- UVify Unveils the Groundbreaking SLAMDAQ
- Dancing Numbers Unveils Google Sheets QuickBooks Integration, Streamlining Data Import, Export, and Deletion
- ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon
- Bitcoin Mining Capacity Reaches 350 Exahashes/second
- Up To 70% Off! Alibonnie Graduation Season Wig Surprise Discount
- Gemini IT Producer Software is Reshaping the Filmmaking Industry